ESR1 and metastatic neoplasm: Given the high frequency and availability of effective therapies targeting ESR1, current guidelines from the National Comprehensive Cancer Network, American Society of Clinical Oncology, and European Society for Medical Oncology recommend testing for ESR1 mutations at each stage of metastatic disease progression (1–4).